Vetenskapliga publikationer

Relaterat till epigenetisk modulering och HDACi:

Histone deacetylase inhibitors for cardiovascular conditions and healthy longevity.

João Pedro Ferreira, Bertram Pitt, Faiez Zannad.
The Lancet Healthy Longevity, Volume 2, Issue 6, 2021, pages e371-e379, ISSN 2666-7568, doi.org/10.1016/S2666-7568(21)00061-1.

Relaterat till CS1s Fas I-studie:

A First in Class Treatment for Thrombosis Prevention. A Phase I study with CS1, a New Controlled Release Formulation of Sodium Valproate

Niklas Bergh, Jan-Peter Idström, Henri Hansson, Jonas Faijerson-Säljö, Björn Dahlöf.
Journal of Cardiology and Vascular Medicine 2019 Volume 5: 1-12.

Relaterat till CS1s Fas II-studie:

Investigation of efficacy, safety and optimal dose of CS1 in subjects with pulmonary arterial hypertension: a prospective, randomized, multicenter, parallel-group phase II study

Raymond Benza, Niklas Bergh, Philip Adamson, Björn Dahlöf. PVRI congress 2022.

Relaterat till läkemedelskandidat CS585:

CS585 is a first-in-class compound targeting the IP receptor for prevention of thrombosis without increased risk of bleeding

Sylviane Lambert, Reheman Adili, Pooja Yalavarthi, Nicole Rhoads, Björn Dahlöf, Andrew White, Niklas Bergh, Michael Holinstat. HemaSphere, 2022; 6:S3.